GLP-1receptor agonists represent a breakthrough for managing type-2 diabetes andobesity, offering metabolic benefits across multiple organ systems. These medications provide effective glycaemic control, significant weight reduction, and ...
Summary Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus andobesity.
Long-TermGLP-1Anti-ObesityUse Data - So Far Semaglutide As part of the STEP (Semaglutide Treatment Effect in People withObesity) clinical trial program to assess the safety and efficacy of semaglutide, the STEP 5 trial represents the most extensive study on the use of semaglutide for weight management to date.
In this Perspective, Ariana Chao, Adam Gilden and Thomas Wadden discuss why alongside the rising popularity of glucagon-like peptide1(GLP-1)-based medications forobesity, there are also concerns about side effects, long-term outcomes, and unregulated products.
This review investigates the side effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) like liraglutide, semaglutide, and tirzepatide, medications known for their efficacy in promoting weight loss among individuals withobesity. The rationale is rooted in understanding the balance between their therapeutic benefits and associated risks.
This particular example perfectly highlights why Glp-1 Antagonist And Obesity Studies is so captivating.
Not justGLP-1: Peptide-drug conjugate hits 5obesitytargets Researchers combine pan-PPAR and dual-incretin receptor agonists for dramatic weight loss in mice
This Viewpoint discusses the optimal treatment duration of glucagon-like peptide-1 receptor agonists in people withobesityandthe benefits of off-ramping, the tapering of these antiobesity medications following an initial treatment period.
